Navigation Links
Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend

Irvine, CA (PRWEB) September 20, 2013

Proove Biosciences, Inc., the leading personalized pain medicine laboratory, is excited to announce that they will be attending and exhibiting at the California Society of Interventional Pain Physician’s 4th Annual Meeting this weekend at the Terranea Resort in Rancho Palos Verdes, California. The event will be held from September 20th to September 22nd.

CASIPP is a growing advocacy society working for interventional pain management physicians and their staff within the state of California. The organization’s mission is to promote the development and practice of safe, high quality, cost-effective interventional pain medicine techniques for the diagnosis and treatment of pain and related disorders, and ensure patient access to these interventions.

“We are proud to support Dr. Ray d'Amours, the President and Executive Director of CASIPP in this important conference,” explains Proove CEO and founder, Brian Meshkin. “Proove is a research-driven company committed to realizing the potential of personalized pain medicine. We are proud to stand with Dr. d’Amours and his colleagues at the forefront of pain medicine genetics. We continue to be the only company to present clinical research on the genetics of pain medicine at scientific meetings throughout the year including, PAINWeek, the American Pain Society, American Society of Addiction Medicine, and other major scientific meetings on pain management.”

Proove Biosciences will be exhibiting at CASIPP and sharing information on its proprietary genetic testing services, including the Proove Narcotic Risk Genetics test that helps physicians identify genetic predisposition to misuse of prescription narcotic pain medications and the Proove Drug Metabolism Genetics test that helps physicians understand the genetic predisposition to drug metabolism.

The meeting will consist of a variety of lectures, workshops, and speakers that cover topics ranging from pain management and therapy optimization, to the current political landscape of California pain management and treatment. Additionally, there will be opportunities for Continued Medical Education (CME) credit.

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
5. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
9. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
10. Ambit Biosciences to Present at Two Upcoming Investor Conferences
11. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
Breaking Biology News(10 mins):